Skip to Main Content

AnaptysBio (ANAB) said Monday that its experimental peanut allergy injection improved tolerance in just under half the patients treated, but the mid-stage study results — dubbed “positive” by the company — benefited from a generous data analysis plan.

In the company’s telling, six of 13 people (46 percent) with moderate-to-severe peanut allergy at the start of the study improved peanut tolerance to a cumulative dose of 500 mg after 14 days following single intravenous injection of ANB020.


Three patients were also treated with a placebo and none were able to tolerate 500 mg of peanut protein.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!